A Phase 2 Study To Evaluate The Safety, Tolerability And Efficacy Of Levofloxacin Inhalation Solution (MP-376) Administered For 5 Days Every 28 Days To Prevent Acute Exacerbations In High Risk COPD Patients
american thoracic society international conference（2012）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要